- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 237/08 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 237/08
Total number of patents in this class: 226
10-year publication summary
|
13
|
12
|
12
|
19
|
15
|
19
|
14
|
28
|
13
|
15
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4833 |
16 |
| Arvinas Operations, Inc. | 242 |
7 |
| Nodthera Limited | 40 |
7 |
| The Board of Trustees of the Leland Stanford Junior University | 6522 |
6 |
| Nippon Soda Co., Ltd. | 890 |
6 |
| F. Hoffmann-La Roche AG | 7931 |
5 |
| Sumitomo Chemical Company, Limited | 9105 |
5 |
| Mitsubishi Tanabe Pharma Corporation | 558 |
5 |
| Genentech, Inc. | 4006 |
4 |
| Syngenta Crop Protection AG | 6229 |
4 |
| Bayer Pharma AG | 1048 |
4 |
| Idemitsu Kosan Co., Ltd. | 4223 |
4 |
| Constellation Pharmaceuticals, Inc. | 211 |
4 |
| Imago Biosciences, Inc. | 38 |
4 |
| BASF SE | 21083 |
3 |
| LG Chem, Ltd. | 17685 |
3 |
| E. I. du Pont de Nemours and Company | 3913 |
3 |
| CHDI Foundation, Inc. | 106 |
3 |
| Dana-Farber Cancer Institute, Inc. | 2620 |
3 |
| Kissei Pharmaceutical Co., Ltd. | 179 |
3 |
| Other owners | 127 |